A Phase 2 study of the antibody-radionuclide-conjugate 177Lu-DOTA-HH1 (Betalutin) in patients with CD37-positive relapsed follicular lymphoma

Trial Profile

A Phase 2 study of the antibody-radionuclide-conjugate 177Lu-DOTA-HH1 (Betalutin) in patients with CD37-positive relapsed follicular lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2016

At a glance

  • Drugs Lutetium-(177lu) lilotomab satetraxetan (Primary) ; Rituximab (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Sponsors Nordic Nanovector
  • Most Recent Events

    • 02 Mar 2016 Status changed from recruiting to completed, as reported by European Clinical Trials Database record.
    • 02 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top